Heart Disease Trial, Recruiting NCT07160491 Sponsor: Shenyang Northern Hospital Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT07160491
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 80 years old
  • People who have had chest pain lasting more than 30 minutes, starting within the last 12 hours
  • People whose heart tracing (ECG) shows a specific pattern of abnormal electrical activity across two or more connected areas of the heart, indicating a type of heart attack known as STEMI
  • People whose treating doctors determine that a key step in the emergency heart procedure (threading a wire through the blocked blood vessel) cannot be performed within 120 minutes of diagnosis
  • People who have signed a form agreeing to take part in the trial

Who may not be able to join:

  • People whose heart has developed a rupture
  • People whose heart tracing shows a specific electrical pattern called complete left bundle branch block, or who have a pacemaker controlling their heart rhythm
  • People for whom clot-dissolving treatment (thrombolysis) is considered unsafe or unsuitable
  • People who have other serious health conditions alongside their heart condition
  • People who have complex heart disease
  • People whose situation is considered unsuitable for participation in a clinical trial for other reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yaling Han, MD,PhD, Northern Theater Command General Hospital of the People's Liberation Army

Phone: +8615309880917

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shenyang Northern Hospital
Registry
ClinicalTrials.gov
Start date
8 September 2025
Est. completion
31 July 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of major adverse events (MAEs) at 1 year

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov